A new way to treat lung cancer with a specific genetic change
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer
This research is exploring a new medicine to help patients with a type of lung cancer that has a specific genetic mutation called SMARCA4.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11109644 on NIH RePORTER |
What this research studies
Lung cancer remains a leading cause of death, and many patients still need better treatment options. This project focuses on a particular type of non-small cell lung cancer where a gene called SMARCA4 is mutated, which happens in a significant number of cases. Researchers have found that targeting a related gene, SMARCA2, could be a promising approach for these specific cancers. We are developing a new type of medicine, called YD23, designed to specifically break down SMARCA2, and early results show it can stop the growth of SMARCA4-mutant lung cancer cells. The goal is to gather more information to prepare this new medicine for future use in patients.
Who could benefit from this research
Good fit: This research is focused on patients with non-small cell lung cancer who have a specific genetic mutation in the SMARCA4 gene.
Not a fit: Patients whose lung cancer does not have the SMARCA4 mutation may not benefit from this specific therapeutic approach.
Why it matters
Potential benefit: If successful, this research could lead to a new, targeted treatment option for patients with SMARCA4-mutant lung cancer.
How similar studies have performed: While the specific molecule YD23 is novel, previous research and early findings from this team suggest that targeting SMARCA2 could be an effective strategy for SMARCA4-mutant cancers.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Lissanu, Yonathan — University of Tx Md Anderson Can Ctr
- Study coordinator: Lissanu, Yonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.